Avenue Therapeutics Inc (ATXI) Directors and Executive Officers

Officers & Directors

Neil Herskowitz
Director

Curtis Oltmans
Director

Faith Charles
Director

Lindsay A. Rosenwald, M.D.
Director

David Jin
Interim Chief Financial Officer and Chief Operating Officer

Jay Kranzler, M.D., Ph.D.
Chairman of the Board

Alexandra MacLean, M.D.
Chief Executive Officer and Director ,

Avenue Therapeutics Inc currently has 1 employees.

News about Avenue Therapeutics Inc Key Personnel

Avenue Therapeutics Makes Breakthrough in Absence Epilepsy Treatment, Despite Financial Setback

In an exciting development for the healthcare industry, Avenue Therapeutics has recently published a groundbreaking study showcasing the preclinical data of their first-in-class drug, BAER-101, in the treatment of absence epilepsy. The drug has demonstrated a unique ability to significantly suppress seizures in a translational model of absence epilepsy, utilizing the Genetic Absence Epilepsy Rat from Strasbourg (GAERS) model. While this achievement is remarkable, it comes at a time when the company has faced financial challenges, recording a substantial net loss of $11 million and experiencing a negative return on assets (ROA) of -246.79% during the past 12 months.
Facts:
1. Avenue Therapeu...

Avenue Therapeutics Secures $5 Million in Proceeds through Warrant Exercise to Fuel Neurologic Disease Therapies

Avenue Therapeutics Raises $5 Million in Proceeds through Warrant Exercise Transactions
Miami, January 5, 2024 - Avenue Therapeutics, a specialty pharmaceutical company specializing in the development and commercialization of therapies for neurologic diseases, has announced its entry into warrant exercise agreements with existing accredited investors. Under these agreements, certain outstanding warrants to purchase a total of 16.5 million shares of the company s common stock will be immediately exercised.
The warrants for immediate exercise include the November 2023 Series B warrants, allowing the purchase of 14.6 million shares of common stock at an exercise price of $0.3006 per share, and the Jan...